Additional studies have revealed that METTL1 regulates PKM2 expression through m7G modification, subsequently activating CD155 and promoting immune evasion in CRC, thus providing a new potential target for prognosis evaluation and immunotherapy in CRC (109). This evidence concerns the gene PKM and colorectal carcinoma.